AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03136198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilator
Description: IV, topical, or SL Vasodilator
Study NCT03136198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasodilator
Description: IV, topical, or SL Vasodilator
Study NCT03136198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive Ventilation (NIV)
Description: Face, mouth, or nasal mask applied to provide positive pressure ventilation
Study NCT03136198 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non invasive Ventilation (NIV)
Description: Face, mouth, or nasal mask applied to provide positive pressure ventilation
Study NCT01503788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
Study NCT04546646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercises
Description: Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
Study NCT01759914 — intervention group
Intervention type: DRUG
Intervention: Potent topical steroid
Study NCT01759914 — intervention group
Intervention type: DRUG
Intervention: Superpotent topical steroid
Study NCT01963468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early language intervention
Description: Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
Study NCT00346437 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study NCT00346437 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Ad5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study NCT00514696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
Study NCT03073759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTCS
Description: Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
Study NCT03073759 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will administer a sham.
Study NCT03754543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe54
Description: Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
Study NCT03754543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Labeled iron salt Fe54
Description: Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
Study NCT03754543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe57
Description: Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
Study NCT03754543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe58
Description: Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
Study NCT04285411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuracy of the VitalDetect™ pulse oximetry system
Description: The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
Study NCT03197129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory adapted waiting room
Description: The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
Study NCT02760888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive a oral Tramadol 100mg 1 hour before the procedure
Study NCT02760888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral Diclofenac 100mg 1 hour before the procedure
Study NCT02760888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive a Placebo 1 hour before the procedure
Study NCT04744623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
Description: 10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
Study NCT02685930 — intervention group
Intervention type: BEHAVIORAL
Intervention: Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy
Description: ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
Study NCT04732234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
Study NCT04732234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
Study NCT01022606 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial sampling
Description: Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
Study NCT02339636 — intervention group
Intervention type: OTHER
Intervention: PDUS examination
Study NCT01772862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors
Study NCT01860989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 75mg single dose
Study NCT01860989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 150mg single dose
Study NCT01860989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 225mg single dose
Study NCT01860989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 300mg single dose
Study NCT02422758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket
Description: 3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
Study NCT02422758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Prewarming
Study NCT03680027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut-enriched Group
Description: All subjects supplemented with 40 g/day of walnuts for 6 weeks.
Study NCT03401957 — intervention group
Intervention type: DRUG
Intervention: Cetuximab
Description: Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
Study NCT03401957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liquid biopsy
Description: The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 1
Description: measurement in supine position
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Trendelenburg-position (ATB)
Description: measurement under ATB
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB in narcosis
Description: measurement under ATB in narcosis
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 1
Description: measurement in supine position in narcosis
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: measurement under passive leg raising
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume bolus substitution
Description: measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 2
Description: measurement in supine position
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: start capnoperitoneum
Description: measurement in supine position
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum
Description: measurement under ATB plus capnoperitoneum
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum plus volume bolus substitution
Description: measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB loss of capnoperitoneum
Description: measurement under ATB
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline
Description: measurement in supine position
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 2
Description: measurement in supine position
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the beginning
Description: measurement in the recovery unit
Study NCT03184272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the end
Description: measurement in the recovery unit
Study NCT05345080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-Reduction Intervention
Description: The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
Study NCT00836108 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: breathing strategy
Description: Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
Study NCT00836108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing strategy
Description: Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
Study NCT02804893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Thorax thoracoscopic surgery (lobectomy)
Study NCT02804893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RATS
Description: Thorax robotic surgery (lobectomy)
Study NCT01346306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith Company - direct current stimulator
Description: Direct current stimulation montage 1.
Study NCT01346306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith Company - direct current stimulator
Description: Direct current stimulation montage 2.
Study NCT03246945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions on taking photographs provided, see methods
Description: Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
Study NCT01976208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.
Study NCT01976208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04233229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ
Description: closed-loop in patients at home for three months
Study NCT04233229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home healthcare services
Description: home healthcare services from Air Liquide in patients at home for three months
Study NCT04233229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care for daily insulin treatment
Description: multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
Study NCT01147445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
Study NCT00678457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron (4 μg/kg b.i.d.)
Study NCT00678457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine (9, 18, and 36 μg/kg)
Study NCT00678457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04646629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment.
Study NCT04646629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group
Study NCT01738958 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L. retueri
Description: two tablets a day for 6 weeks
Study NCT01738958 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01919853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Study NCT01919853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study NCT02523209 — intervention group
Intervention type: DEVICE
Intervention: HR-pQCT
Description: HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
Study NCT02523209 — intervention group
Intervention type: DEVICE
Intervention: DEXA
Description: The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
Study NCT03826615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
Study NCT03931070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
Study NCT03931070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
Study NCT02750722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter®
Description: Acute exercise with Flutter® breathing therapy.
Study NCT02750722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Flutter®
Description: Acute exercise without Flutter® breathing therapy.
Study NCT04081181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
Study NCT04208230 — intervention group
Intervention type: DEVICE
Intervention: XtremeCT
Description: HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
Study NCT03989544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT00297401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32 mg, QD, PO, up to 8 weeks